NCT03205761: Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer

NCT03205761
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must have documented methylation of BRCA1/2 promoters
Exclusions: Deleterious germline mutations in BRCA1/2; Symptomatic uncontrolled brain metastases- see trial for details
https://ClinicalTrials.gov/show/NCT03205761

Comments are closed.

Up ↑